An observational study in Mother to Child Transmission of HIV, sponsored by ANRS, Emerging Infectious Diseases. Status unknown at 52 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.
Sponsored by ANRS, Emerging Infectious Diseases · Observational
The purpose of this study is to provide a surveillance system to monitor changes in the rate of mother to child HIV transmission and preventive practices in France and especially to identify the occurrence of toxicity in children exposed perinatally to antiretroviral drugs.
The goal of the CO11 national cohort is to provide with CO1 a wider surveillance system to monitor changes in the rate of mother to child transmission and preventive practices in France and especially to identify the occurrence of toxicity in children exposed perinatally to antiretroviral drugs.
The CO11 EPF enrolle HIV infected women who delivery in maternity generally smaller than CO1 maternity (15 sites in Paris area, 35 in mainland France and 4 in the DOM).
Maternal clinical, biological and therapeutic data before and during pregnancy were collected at delivery, with simplified questionnaires.
The children are examined clinically and biologically at birth, 6, 12 and 24 months.
ANRS, Emerging Infectious Diseases is the lead sponsor of 215 studies on the registry; 38 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion as soon as possible during pregnancy of HIV-women in obstetrical sites (15 sites in Paris area, 35 in mainland France and 4 in the DOM)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Efficacy of PMTCT strategies by measuring rate of mother to child transmission of HIV
Number of infected children (HIV RNA \>50c/mL or Positive serology) reported on the total number of children
Time frame: At birth up to 24 months
Immuno-virological response during pregnancy
HIV ARN \<50c/mL, CD4 cells count\>500 cells/mL
Time frame: At inclusion up to childbirth
Tolerance and toxicity of different kind of MTCT prophylaxis during pregnancy
incidence of pathologies during pregnancy
Time frame: At inclusion up to childbirth
Impact of different kind of MTCT prophylaxis on childbirth
Childbirth mode (Number of emergency Caesarean section, Number of planned caesarean section)
Time frame: At delivery
Impact of different kind of MTCT prophylaxis during pregnancy on uninfected children
Clinical abnormalities (occurrence of adverse events)
Time frame: At childbirth, 1 month, 3 months, 6 months, 12 months and 18-24 months
The record gives a start of Jun 2005, a primary completion of Mar 2023 and a completion of Mar 2023. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ANRS, Emerging Infectious Diseases →